Pfizer Halts Trial Over Safety Concerns
Pfizer has been asked by the FDA to suspend chronic pain studies involving tanezumab because of safety concerns.
Pfizer has been asked by the FDA to suspend chronic pain studies involving tanezumab because of safety concerns. The investigational compound had been touted by some as a potential blockbuster.
Tanezumab’s problems began last month when an osteoarthritis clinical trial was halted following reports that some patients’ osteoarthritis had worsened, necessitating joint replacement. In its press statement, Pfizer claimed that the adverse event had not been observed in non-osteoarthritis patient populations.
However, the FDA has further considered the reports and is concerned that there is potential for such events to occur in other patient populations in which the compound is being studied. As such, Pfizer has suspended its tanezumab studies for chronic low back pain and painful diabetic peripheral neuropathy, although it will continue investigation of the compound in some areas of high unmet medical need, such as cancer pain.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
